All News
ACR’s Run at Goliath (PCPs) (5.31.2024)
Dr. Jack Cush reviews the journal reports and articles from this past week on RheumNow.com. The ACR (and Cush) address their new website designed to educate PCPs and APPs - what do you think?
Read Article
Metformin Lowers Gout Risk in Pre-Diabetes
A large, propensity score-matched cohort study shows that metformin use in patients with pre-diabetes significantly lowers the risk of future gout.
Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis
A single center study demonstrates that biologic treatment of psoriasis (PsO) significantly reduces the likelihood of psoriatic arthritis (PsA) development; suggesting a role for more aggressive treatment of PsO.
ACR Website to Support Primary Care Practitioners
d
ACR
The American College of Rheumatology recently launched Rheumatology for Primary Care, a new resource for primary care physicians (PCP) and advanced practice providers (APP) offering them expanded support and guid
Read Article
Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis
A single center study demonstrates that biologic treatment of PsO significantly reduces the likelihood of PsA development; suggesting a role for more aggressive treatment of PsO.
https://t.co/VHk2KEsP8d https://t.co/1r4zVAzrMw
Dr. John Cush RheumNow ( View Tweet)
ACR Website to Support PCPs
The American College of Rheumatology recently launched Rheumatology for Primary Care, a new resource for PCP and APP offering them expanded support and guidance to identify rheumatic diseases in their patients.
https://t.co/yZbpG3598O https://t.co/S4oYNMrdqt
Dr. John Cush RheumNow ( View Tweet)
Colchicine prophylaxis w/ allopurinol (“start-low go-slow” 100mg escalation strategy), is best used in pts w/ gout flare in month prior to allopurinol. Longer prophylaxis may be required w/ ongoing flares in 1st 6mos of allopurinol if T2T not achieved https://t.co/qWUwrAcCJZ https://t.co/6S7Y6p7BnF
Dr. John Cush RheumNow ( View Tweet)
Ramosetron,a 5-HT3 recept antagonist used for post-op N/V,t has been used for adjunctive pain Rx & IBS. An 80 FM pt DBRCT tested PBO vs Ramosetron (.3 mg/day IV x5d). @d5 had signif better VAS pain (1.18 vs 0.54, p< 0.05), but didnt persist till day 28 https://t.co/0ABduv8Nlq https://t.co/WGlxIhst1o
Dr. John Cush RheumNow ( View Tweet)
Anakinra in COVID showed mixed (often negative) results. But this Turkish retrospective observational study comparing standard of care to IV anakinra in severe COVID pts. IV ANAK had less thromboembolic event (5% vs 12.3%, p = 0.038), better survival https://t.co/4webWJKEfB https://t.co/85GnCd6N8O
Dr. John Cush RheumNow ( View Tweet)
Forbes on the future of CAR-T cell therapy - A Gamechanger For Autoimmune Diseases. Innovation, costs, more trials and regulatory differences for autoimmune (vs cancer) patietns? https://t.co/1Yg40HPTzh https://t.co/NqCwEzmZ1g
Links:
Dr. John Cush RheumNow ( View Tweet)
There's a huge difference between knowing the name of something and knowing something.
We talk in fact-deficient, obfuscating generalities to cover up our lack of understanding.
Prof. Feynman ProfFeynman ( View Tweet)
#JuneIssue | Relapsing polychondritis is challenging to diagnosis owing to overlapping symptoms with other conditions
Learn more about the clinical features and differential diagnoses in this #Review
https://t.co/iXl9rQ0ONS
NatRevRheumatol NatRevRheumatol ( View Tweet)
Kaiser/California EHR study of #SLE pregnancies (2011-2020) - 657 pregnancies in 453 prs; The live birth rate = 74%, 23% w/ Spontaneous Ab, 2% ectopic/molar & <1% stillbirths. Variable outcomes by race & ethnicity, aPL status & nephritis history https://t.co/gvmYpTuFon https://t.co/9TeG8kfLmK
Dr. John Cush RheumNow ( View Tweet)
JAMA full read comprehensive review of 'Chronic Pruritus' affecting 22%, 1% of all out pt visits
- Dx algorithm
- Pathophys
- Rx options
- Alternative Rx
https://t.co/4sd2HqUX9Y https://t.co/FoVHFnfEPa
Links:
Dr. John Cush RheumNow ( View Tweet)
Do you have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/qvVEUoNYi5 https://t.co/duw6jg5xpp
Dr. John Cush RheumNow ( View Tweet)
Hypertension not associated with High NSAID Doses in AxSpA
At the SPARTAN meeting, Dr.Meade-Aguilar reported that amongst axSpA patients receiving NSAIDs, there was no diff in the risk for hypertension when comparing those on high vs. low dose NSAIDs.
https://t.co/UsRfobVHO7 https://t.co/fGj5yO53Yk
Dr. John Cush RheumNow ( View Tweet)
Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/vEQUZGAuJe
Dr. John Cush RheumNow ( View Tweet)
2 large 48-wk phase 3 trials (Be HEARD I/II) of Bimekizumab vs PBO in moderate-to-severe hidradenitis suppurativa shows BKZ to be safe & significantly effective (48% vs 29% & 52% vs 32%) vs PBO. https://t.co/xPXUd9vHyE https://t.co/uESOGYhAdw
Dr. John Cush RheumNow ( View Tweet)
Most leaders value loyalty. Great leaders put a higher premium on integrity.
Loyalty is allegiance to power. You're expected to show deference and follow orders.
Integrity is allegiance to principles. You're expected to challenge orders that violate your mission or values.
Adam Grant AdamMGrant ( View Tweet)
No Great Options for Treating VEXAS
For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
https://t.co/tjCX1STnnD https://t.co/Bn40Nfxy9Y
Dr. John Cush RheumNow ( View Tweet)